Trapping Poly(ADP-Ribose) Polymerase

  title={Trapping Poly(ADP-Ribose) Polymerase},
  author={Yuqiao Shen and Mika Aoyagi-Scharber and Bing Ke Wang},
  journal={The Journal of Pharmacology and Experimental Therapeutics},
  pages={446 - 457}
Recent findings indicate that a major mechanism by which poly(ADP-ribose) polymerase (PARP) inhibitors kill cancer cells is by trapping PARP1 and PARP2 to the sites of DNA damage. The PARP enzyme-inhibitor complex “locks” onto damaged DNA and prevents DNA repair, replication, and transcription, leading to cell death. Several clinical-stage PARP inhibitors, including veliparib, rucaparib, olaparib, niraparib, and talazoparib, have been evaluated for their PARP-trapping activity. Although they… 

Figures from this paper

Poly(ADP-ribose) polymerase inhibition: past, present and future

A timeline of PARP biology and medicinal chemistry is provided, which summarizes the pathophysiological processes in which PARP plays a role and highlights key opportunities and challenges in the field, such as counteracting PARP inhibitor resistance during cancer therapy and repurposing PARP inhibitors for the treatment of non-oncological diseases.

Structural basis for allosteric PARP-1 retention on DNA breaks

HXMS experiments revealed that a critical allosteric regulatory domain of PARP-1, the helical domain (HD), is affected in distinct ways depending on the particular PARPi engaged in the NAD+-binding site adjacent to the HD.

Poly(ADP-ribose) polymerase activity and inhibition in cancer.

Synthesis and Evaluation of a Mitochondria-Targeting Poly(ADP-ribose) Polymerase-1 Inhibitor.

XJB-veliparib and analogous mitochondria-targeting PARP inhibitors warrant further evaluation in vitro and in vivo, particularly in conditions where PARP overactivation leads to mitochondrial energy failure and maintenance of genomic DNA integrity is desirable, e.g., ischemia, oxidative stress, and radiation exposure.

Trial watch – inhibiting PARP enzymes for anticancer therapy

The impact ofPARP enzymes and PARylation in cancer, the mechanism of cancer cell killing by PARP1 inactivation, and the results of recent clinical studies aimed at evaluating the safety and therapeutic profile of PARP inhibitors in cancer patients are described.

Poly (ADP-ribose) polymerases inhibitor, Zj6413, as a potential therapeutic agent against breast cancer.

PARP Inhibitors as Therapeutics: Beyond Modulation of PARylation

This review comprehensively address the current state of knowledge regarding the mechanisms of action of PARP inhibitors and the different effects ofPARP inhibitors in combination with cytotoxic chemotherapeutic agents regarding the mechanism of regulating PARylation.

Poly(ADP-ribose) polymerase 1 searches DNA via a ‘monkey bar’ mechanism

It is shown that PARP1 association with DNA is diffusion-limited, and release ofPARP1 from DNA is promoted by binding of an additional DNA molecule that facilitates a “monkey bar” mechanism, also known as intersegment transfer.



Structural Implications for Selective Targeting of PARPs

In this review, current literature that has found ways to gain selectivity for one PARP over another is discussed, and insights into targeting other domains that make up PARPs are provided, and how new classes of drugs could provide a high degree of selectivity by affecting specific cellular functions are provided.

Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors.

This study shows that PARP inhibitors trap the PARP1 and PARP2 enzymes at damaged DNA, providing a new mechanistic foundation for the rational application ofPARP inhibitors in cancer therapy.

Rationale for Poly(ADP-ribose) Polymerase (PARP) Inhibitors in Combination Therapy with Camptothecins or Temozolomide Based on PARP Trapping versus Catalytic Inhibition

It is concluded that catalytic PARP inhibitors are highly effective in combination with camptothecins, whereas PARP inhibitor capable of PARP trapping are more effective with temozolomide.

Enhanced Killing of Cancer Cells by Poly(ADP-ribose) Polymerase Inhibitors and Topoisomerase I Inhibitors Reflects Poisoning of Both Enzymes*

The ability of the PARP inhibitor veliparib to enhance the cytotoxicity of the topoisomerase I poisons topotecan and camptothecin and confirm that PARP1 is the critical target for this sensitization, consistent with a model in which small molecule inhibitors convertPARP1 into a protein that potentiates the effects of topoisomersase I poison by binding to damaged DNA and preventing its normal repair.

PARP inhibitor with selectivity toward ADP-ribosyltransferase ARTD3/PARP3.

The results show that by targeting the nicotinamide binding site, selective inhibition can be achieved among the closest relatives of the validated clinical target, ADP-ribosyltransferase-1/poly(ADp-ribose) polymerase- 1.

PARP-1 and PARP-2: New players in tumour development.

Emerging information is highlighted about the redundant and specific functions of PARP-1 andPARP-2 in genome surveillance and DNA repair pathways that might provide invaluable clues to design new cancer therapeutic approaches.

Evolution of poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors. From concept to clinic.

The major PARP-1 medicinal chemistry programs will be highlighted focusing on the lead generation, lead optimization, candidate selection, and clinical progress, most of which predated the disclosure of clinical candidate structures and recent clinical trial results.

PARP1–TDP1 coupling for the repair of topoisomerase I–induced DNA damage

PARP1 is identified as a key component driving the repair of trapped Top1cc by TDP1, and is shown to play a critical role in this process.

PARP-1 mechanism for coupling DNA damage detection to poly(ADP-ribose) synthesis.

Stereospecific PARP Trapping by BMN 673 and Comparison with Olaparib and Rucaparib

BMN 673 is the most potent clinical PARP inhibitor tested to date with the highest efficiency at trapping PARP–DNA complexes and is also approximately 100-fold more cytotoxic than olaparib and rucaparIB in combination with the DNA alkylating agents methyl methane sulfonate and temozolomide.